Delcath Systems Release: Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on developing safe and effective treatments for primary and metastatic liver cancers, announces that results from two single-institution studies conducted in Germany of use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with liver metastases were presented as posters at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting.
MORE ON THIS TOPIC